Neuland Laboratories Ltd (NEULANDLAB) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 229993,
    "name": "Neuland Labs.",
    "stock_name": "Neuland Labs.",
    "full_name": "Neuland Laboratories Ltd",
    "name_url": "stocks-analysis/neuland-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "13,391.80",
    "chg": 263.4,
    "chgp": "2.01%",
    "dir": 1,
    "prev_price": "13,128.40",
    "mcapval": "17,181.53 Cr",
    "mcap": "Small Cap",
    "scripcode": 524558,
    "symbol": "NEULANDLAB",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE794A01010",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "36.15 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/neuland-labs-229993-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Neuland Laboratories Sees Robust Trading Activity Amid Sector Outperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-surges-on-high-value-trading-and-institutional-interest-3744307",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NeulandLaborato_most_active_equities_by_value_3744307.png",
        "date": "2025-12-03 13:00:10",
        "description": "Neuland Laboratories Ltd emerged as one of the most actively traded stocks by value on 3 December 2025, registering significant market interest within the Pharmaceuticals & Biotechnology sector. The stock demonstrated notable price movement and trading volumes, outperforming its sector peers and the broader Sensex index during the session."
      },
      {
        "title": "Neuland Labs. Sees Revision in Market Assessment Amid Strong Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/neuland-labs-upgraded-to-buy-by-marketsmojo-on-strong-financial-and-technical-gains-3733280",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NeulandLabs_mojoScore_3733280.png",
        "date": "2025-11-27 10:05:37",
        "description": "Neuland Labs., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation, reflecting shifts in its financial and technical outlook. This adjustment follows notable developments in the company’s operational performance and market positioning."
      },
      {
        "title": "Why is Neuland Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-neuland-labs-fallingrising-3719057",
        "imagepath": "",
        "date": "2025-11-21 00:07:44",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Price Movement and Market Performance</strong></p>\n<p>Neuland Laboratories has experienced a consecutive four-day decline, resulting in a cumulative loss of 3.47% over this period. The stock underperformed its sector by 1.01% on the day, touching an intraday low of ₹16,651.95, which represents a 2.43% drop from previous levels. Notably, the stock’s price remains above its 20-day, 50-day, 100-day, and 200-day moving averages, signalling underlying strength, but it has slipped below the 5-day moving average, indicating short-term selling pressure.</p>\n<p>Investor participation has also waned, with delivery volume on 19 Nov falling sharply by 57.4% compared to the five-day average. This decline in trading activity suggests reduced enthusiasm among investors, which may be contributing..."
      },
      {
        "title": "Neuland Laboratories Hits New 52-Week High of Rs. 19,748.4",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-hits-new-52-week-high-of-rs-197484-3685160",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NeulandLaborato_priceRelatedfactors_3685160.png",
        "date": "2025-11-10 10:28:59",
        "description": "Neuland Laboratories has achieved a new 52-week high, reflecting strong performance in the pharmaceutical sector. The company has shown consistent upward momentum, with significant gains over recent days. It has delivered impressive financial results and maintains high institutional holdings, indicating a solid market position."
      },
      {
        "title": "Neuland Laboratories Hits New 52-Week High of Rs. 19,748.4",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-hits-new-52-week-high-of-rs-197484-3685168",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NeulandLaborato_priceRelatedfactors_3685168.png",
        "date": "2025-11-10 10:28:51",
        "description": "Neuland Laboratories has achieved a new 52-week high, reflecting strong performance in the pharmaceutical sector. The company has shown consistent upward momentum, with significant gains over recent days. It reported impressive financial metrics, including record operating cash flow and net sales, highlighting its growth potential and stability."
      },
      {
        "title": "Neuland Laboratories Ltd Surges 6.52% with Rs 39.07 Lakhs in Trade Value Today",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-ltd-surges-652-with-rs-3907-lakhs-in-trade-value-today-3684896",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NeulandLaborato_most_active_equities_by_value_3684896.png",
        "date": "2025-11-10 10:00:09",
        "description": "Neuland Laboratories Ltd has become one of the most active stocks in the Pharmaceuticals & Biotechnology sector, with a trading volume of 204,411 shares and a market capitalization of Rs 22,786 crore. The stock has shown strong performance, reaching a new 52-week high and trading above key moving averages."
      },
      {
        "title": "Neuland Laboratories Soars to All-Time High, Signaling Unmatched Market Confidence",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-soars-to-all-time-high-signaling-unmatched-market-confidence-3684707",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NeulandLaborato_priceRelatedfactors_3684707.png",
        "date": "2025-11-10 09:30:57",
        "description": "Neuland Laboratories has reached an all-time high, showcasing its strong position in the Pharmaceuticals & Biotechnology sector. The stock has demonstrated impressive momentum, with significant gains over recent days and a high level of intraday volatility. The company also boasts strong financial metrics and high institutional holdings."
      },
      {
        "title": "How has been the historical performance of Neuland Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-neuland-labs-3683407",
        "imagepath": "",
        "date": "2025-11-09 22:36:06",
        "description": "Answer:\nThe historical performance of Neuland Labs shows a fluctuating trend in key financial metrics over the years.\n\nBreakdown:\nNeuland Labs' net sales peaked at 1,558.58 Cr in March 2024 but declined to 1,476.84 Cr by March 2025. The total operating income followed a similar pattern, reaching 1,558.58 Cr in March 2024 before dropping to 1,476.84 Cr in March 2025. Raw material costs increased from 360.44 Cr in March 2019 to 574.81 Cr in March 2025, while employee costs rose from 110.46 Cr in March 2019 to 272.00 Cr in March 2025. Operating profit (PBDIT) saw a decline from 475.13 Cr in March 2024 to 343.78 Cr in March 2025, with a corresponding decrease in profit before tax from 401.44 Cr to 346.33 Cr. Profit after tax also fell from 300.08 Cr in March 2024 to 260.11 Cr in March 2025. The company's total assets increased significantly from 1,230.98 Cr in March 2020 to 2,179.88 Cr in March 2025, while tota..."
      }
    ],
    "total": 708,
    "sid": "229993",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/neuland-laboratories-229993"
  },
  "announcements": [
    {
      "caption": "Intimation Regarding Conversion Of Statutory AuditorS Firm To A Limited Liability Partnership (LLP)",
      "datetime": "30-Jan-2026",
      "details": "Intimation regarding conversion of Statutory Auditors Firm to a LLP",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "27-Jan-2026",
      "details": "Q3FY26 Earnings Call Intimation",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025",
      "datetime": "21-Jan-2026",
      "details": "Neuland Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 inter alia to consider and approve The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Neuland Laboratories Ltd has declared <strong>120%</strong> dividend, ex-date: 18 Jul 25",
          "dt": "2025-07-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Neuland Laboratories Ltd has announced <strong>4:25</strong> rights issue, ex-date: 13 Aug 14",
          "dt": "2014-08-13",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Neuland Laboratories Sees Robust Trading Activity Amid Sector Outperformance

2025-12-03 13:00:10

Neuland Laboratories Ltd emerged as one of the most actively traded stocks by value on 3 December 2025, registering significant market interest within the Pharmaceuticals & Biotechnology sector. The stock demonstrated notable price movement and trading volumes, outperforming its sector peers and the broader Sensex index during the session.

Neuland Labs. Sees Revision in Market Assessment Amid Strong Financial Trends

2025-11-27 10:05:37

Neuland Labs., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation, reflecting shifts in its financial and technical outlook. This adjustment follows notable developments in the company’s operational performance and market positioning.

Why is Neuland Labs. falling/rising?

2025-11-21 00:07:44

Short-Term Price Movement and Market Performance Neuland Laboratories has experienced a consecutive four-day decline, resulting in a cumulative loss of 3.47% over this period. The stock underperformed its sector by 1.01% on the day, touching an intraday low of ₹16,651.95, which represents a 2.43% drop from previous levels. Notably, the stock’s price remains above its 20-day, 50-day, 100-day, and 200-day moving averages, signalling underlying strength, but it has slipped below the 5-day moving average, indicating short-term selling pressure. Investor participation has also waned, with delivery volume on 19 Nov falling sharply by 57.4% compared to the five-day average. This decline in trading activity suggests reduced enthusiasm among investors, which may be contributing...

Neuland Laboratories Hits New 52-Week High of Rs. 19,748.4

2025-11-10 10:28:59

Neuland Laboratories has achieved a new 52-week high, reflecting strong performance in the pharmaceutical sector. The company has shown consistent upward momentum, with significant gains over recent days. It has delivered impressive financial results and maintains high institutional holdings, indicating a solid market position.

Neuland Laboratories Hits New 52-Week High of Rs. 19,748.4

2025-11-10 10:28:51

Neuland Laboratories has achieved a new 52-week high, reflecting strong performance in the pharmaceutical sector. The company has shown consistent upward momentum, with significant gains over recent days. It reported impressive financial metrics, including record operating cash flow and net sales, highlighting its growth potential and stability.

Neuland Laboratories Ltd Surges 6.52% with Rs 39.07 Lakhs in Trade Value Today

2025-11-10 10:00:09

Neuland Laboratories Ltd has become one of the most active stocks in the Pharmaceuticals & Biotechnology sector, with a trading volume of 204,411 shares and a market capitalization of Rs 22,786 crore. The stock has shown strong performance, reaching a new 52-week high and trading above key moving averages.

Neuland Laboratories Soars to All-Time High, Signaling Unmatched Market Confidence

2025-11-10 09:30:57

Neuland Laboratories has reached an all-time high, showcasing its strong position in the Pharmaceuticals & Biotechnology sector. The stock has demonstrated impressive momentum, with significant gains over recent days and a high level of intraday volatility. The company also boasts strong financial metrics and high institutional holdings.

How has been the historical performance of Neuland Labs.?

2025-11-09 22:36:06

Answer: The historical performance of Neuland Labs shows a fluctuating trend in key financial metrics over the years. Breakdown: Neuland Labs' net sales peaked at 1,558.58 Cr in March 2024 but declined to 1,476.84 Cr by March 2025. The total operating income followed a similar pattern, reaching 1,558.58 Cr in March 2024 before dropping to 1,476.84 Cr in March 2025. Raw material costs increased from 360.44 Cr in March 2019 to 574.81 Cr in March 2025, while employee costs rose from 110.46 Cr in March 2019 to 272.00 Cr in March 2025. Operating profit (PBDIT) saw a decline from 475.13 Cr in March 2024 to 343.78 Cr in March 2025, with a corresponding decrease in profit before tax from 401.44 Cr to 346.33 Cr. Profit after tax also fell from 300.08 Cr in March 2024 to 260.11 Cr in March 2025. The company's total assets increased significantly from 1,230.98 Cr in March 2020 to 2,179.88 Cr in March 2025, while tota...

View All News